CLAIMS

1. An epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for use in the adjuvant treatment after tumour resection of a patient with epidermal growth factor receptor-mutation-positive (EGFRm) non-small cell lung cancer (NSCLC) , wherein the EGFR TKI is either a second-generation or third-generation EGFR TKI.

2. An EGFR TKI for use according to claim 1, wherein the patient has been classified with stage II or IIIA EGFRm NSCLC.

3. An EGFR TKI for use according to claim 1 or claim 2, wherein the patient has received adjuvant chemotherapy.


4. An EGFR TKI for use according to any one of claims 1 to 3, wherein the EGFRm NSCLC comprises activating mutations in EGFR selected from exon 19 deletions or exon 21 L858R substitution mutations.

5. An EGFR TKI for use according to any one of claims 1 to 4, wherein the adjuvant EGFR TKI treatment provides improved disease free survival (DFS).

6. An EGFR TKI for use according to any one of claims 1 to 5, wherein the adjuvant EGFR TKI treatment provides a probability of DFS of about 85% to about 95% at about 24 months.

7. An EGFR TKI for use according to any one of claims 1 to 6, wherein the EGFR TKI is a third-generation EGFR TKI.

8. An EGFR TKI for use according to any one of claims 1 to 7, wherein the EGFR TKI is a third-generation EGFR TKI of Formula (I):



(I)

wherein:

G is selected from 4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyridin-3-yl, indol-3-yl, indazol-1-yl, 3,4-dihydro-1H-[1,4]oxazino[4,3-a]indol-10-yl, 6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl, 5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl, pyrrolo[3,2-b]pyridin-3-yl and pyrazolo[1,5-*a*]pyridin-3-yl;

R^1 is selected from hydrogen, fluoro, chloro, methyl and cyano;

R^2 is selected from methoxy, trifluoromethoxy, ethoxy, 2,2,2-trifluoroethoxy and methyl;

R^3 is selected from (3*R*)-3-(dimethylamino)pyrrolidin-1-yl, (3*S*)-3-(dimethyl-amino)pyrrolidin-1-yl, 3-(dimethylamino)azetidin-1-yl, [2-(dimethylamino)ethyl]-(methyl)amino, [2-(methylamino)ethyl](methyl)amino, 2-(dimethylamino)ethoxy, 2-(methylamino)ethoxy, 5-methyl-2,5-diazaspiro[3.4]oct-2-yl, (3a*R*,6a*R*)-5-methylhexa-hydro-pyrrolo[3,4-*b*]pyrrol-1(2*H*)-yl, 1-methyl-1,2,3,6-tetrahydropyridin-4-yl, 4-methylpiperizin-1-yl, 4-[2-(dimethylamino)-2-oxoethyl]piperazin-1-yl, methyl[2-(4-methylpiperazin-1-yl)ethyl]amino, methyl[2-(morpholin-4-yl)ethyl]amino, 1-amino-1,2,3,6-tetrahydropyridin-4-yl and 4-[(2*S*)-2-aminopropanoyl]piperazin-1-yl;

R^4 is selected from hydrogen, 1-piperidinomethyl and N,N-dimethylaminomethyl;

R^5 is independently selected from methyl, ethyl, propyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, fluoro, chloro and cyclopropyl;

X is CH or N; and

n is 0, 1 or 2;

or a pharmaceutically acceptable salt thereof.

9. An EGFR TKI for use according to any one of claims 1 to 7, wherein the third-generation EGFR TKI is selected from the group consisting of osimertinib or a pharmaceutically acceptable salt thereof, AZD3759 or a pharmaceutically acceptable salt thereof, lazertinib or a pharmaceutically acceptable salt thereof, abivertinib or a pharmaceutically acceptable salt thereof, alflutinib or a pharmaceutically acceptable salt thereof, CK-101 or a pharmaceutically acceptable salt thereof, HS-10296 or a pharmaceutically acceptable salt thereof and BPI-7711 or a pharmaceutically acceptable salt thereof.

10. An EGFR TKI for use according to any one of claims 1 to 9, wherein the third generation EGFR TKI is osimertinib, or a pharmaceutically acceptable salt thereof.

11. An EGFR TKI for use according to claim 10, wherein the osimertinib, or a pharmaceutically acceptable salt thereof, is administered once-daily.

12. An EGFR TKI for use according to either claim 10 or claim 11, wherein the osimertinib, or a pharmaceutically acceptable salt thereof, is administered in tablet form.

13. An EGFR TKI for use according to any one of claims 10 to 12, wherein the osimertinib, or a pharmaceutically acceptable salt thereof, is osimertinib mesylate.

14. An EGFR TKI for use according to any one of claims 1 to 6, wherein the EGFR TKI is a second-generation EGFR TKI selected from afatinib and dacomitinib.

15. The use of an EGFR TKI in the manufacture of a medicament for the adjuvant treatment after tumour resection of a patient with epidermal growth factor receptor-mutation-positive (EGFRm) non-small cell lung cancer (NSCLC), wherein the EGFR TKI is either a second-generation or third-generation EGFR TKI.

16. A method of treating a patient with epidermal growth factor receptor-mutation-positive (EGFRm) non-small cell lung cancer (NSCLC), said method comprising the adjuvant treatment after tumour resection of the patient with a second-generation or third-generation EGFR TKI.

17. A method of improving disease-free survival (DFS) in a patient with epidermal growth factor receptor-mutation-positive (EGFRm) non-small cell lung cancer (NSCLC), the method comprising the adjuvant treatment after tumour resection of the patient with a second-generation or third-generation EGFR TKI.